Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers.

Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G, Kumar RV, Manjunath S, Correa M, Srinath BS, Patil S, Prasad MS, Gopinath KS, Rao RN, Violette SM, Weinreb PH, Sridhar TS.

Cancer Med. 2016 Aug;5(8):2000-11. doi: 10.1002/cam4.756. Epub 2016 May 17.

2.

Therapeutic targeting of integrin αvβ6 in breast cancer.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug.

3.

Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.

Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.

Breast Cancer Res. 2017 Jun 30;19(1):74. doi: 10.1186/s13058-017-0868-8.

4.

Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis.

Laurin M, Huber J, Pelletier A, Houalla T, Park M, Fukui Y, Haibe-Kains B, Muller WJ, Côté JF.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7434-9. doi: 10.1073/pnas.1213050110. Epub 2013 Apr 16.

5.

HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.

Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, Ce A, Alexander A, Kaluve RS, Manjunath S, Correa M, Srinath BS, Patil S, Kalamdani A, Prasad M, Sridhar TS.

Tumour Biol. 2017 Mar;39(3):1010428317695028. doi: 10.1177/1010428317695028.

PMID:
28349782
6.

Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis.

Tatler AL, Goodwin AT, Gbolahan O, Saini G, Porte J, John AE, Clifford RL, Violette SM, Weinreb PH, Parfrey H, Wolters PJ, Gauldie J, Kolb M, Jenkins G.

PLoS One. 2016 Aug 5;11(8):e0158047. doi: 10.1371/journal.pone.0158047. eCollection 2016.

7.
8.

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.

Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.

PMID:
28567637
9.

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.

Jang M, Kim E, Choi Y, Lee H, Kim Y, Kim J, Kang E, Kim SW, Kim I, Park S.

Breast Cancer Res. 2012 Aug 3;14(4):R115. doi: 10.1186/bcr3239.

10.

[Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].

Yang M, Xu SP, Ao QL.

Zhonghua Bing Li Xue Za Zhi. 2013 Apr;42(4):257-61. doi: 10.3760/cma.j.issn.0529-5807.2013.04.010. Chinese.

PMID:
23928534
11.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

12.

Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.

Ono M, Tsuda H, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y.

Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.

PMID:
23584595
13.

The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, Blomqvist C, Butt S, Wärnberg F.

BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.

14.

Binding of MMP-9-degraded fibronectin to β6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.

Li W, Liu Z, Zhao C, Zhai L.

Oncol Rep. 2015 Sep;34(3):1345-52. doi: 10.3892/or.2015.4103. Epub 2015 Jul 2.

PMID:
26134759
15.

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.

Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.

Hum Pathol. 2007 Jan;38(1):26-34. Epub 2006 Oct 23.

PMID:
17056098
16.

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.

Lee SJ, Hwang CS, Kim YK, Lee HJ, Ahn SJ, Shin N, Lee JH, Shin DH, Choi KU, Park DY, Lee CH, Huh GY, Sol MY, Lee HJ, Gong G, Kim JY, Kim A.

Cancer Res Treat. 2017 Apr;49(2):313-321. doi: 10.4143/crt.2016.098. Epub 2016 Jul 7.

17.

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.

Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL.

Int J Cancer. 2010 Mar 15;126(6):1445-53. doi: 10.1002/ijc.24826.

18.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

19.
20.

Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).

Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, Batistatou A, Bobos M, Dimopoulos MA, Timotheadou E, Gogas H, Christodoulou C, Papadopoulou K, Efstratiou I, Scopa CD, Papaspyrou I, Vlachodimitropoulos D, Linardou H, Samantas E, Pectasides D, Pavlidis N, Fountzilas G.

PLoS One. 2013 Jul 29;8(7):e70634. doi: 10.1371/journal.pone.0070634. Print 2013.

Supplemental Content

Support Center